Does bepridil create a paradigm shift in the treatment of persistent atrial fibrillation?

Circulation Journal

Volumn 73, Issue 6, 2009, Pages 1008-1009

  Hirao, Kenzo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BEPRIDIL; DRONEDARONE; PLACEBO; VERAPAMIL;

ADULT; BODY WEIGHT; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; EDITORIAL; ELECTROCARDIOGRAM; EMERGENCY WARD; ESOPHAGUS FISTULA; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BEPRIDIL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 67649994258     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0255     Document Type: Editorial

References (10)

1. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-741.
2. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, Crijns HJ, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
3. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475. (Pubitemid 36959891)
4. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
5. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al for the J-BAF Investigators. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: A multicenter, randomized, placebo-controlled, double-blind study (J-BAF study). Circ J 2009; 73: 1020-1027.
6. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008). Circ J 2008; 72(Suppl IV): 1581-1638.
7. Perelman M, McKenna WJ, Rowland E, Krikler DM. A comparison bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 58: 339-344. (Pubitemid 17152512)
8. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
9. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666. (Pubitemid 43797774)
10. Ghia KK, Chugh A, Good E, Pelosi F, Jongnarangsin K, Bogun F, et al. A nationwide survey on the prevalence of atrioesophageal fistula after left atrial radiofrequency catheter ablation. J Interv Card Electrophysiol 2009; 24: 33-36.